Soleus Capital Management’s UroGen Pharma URGN Stock Holding History

Soleus Capital Management’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$30.5M	Buy	829,810 +102,810	+14%	+$2.79M	1.05%	29
2026 Q1	$13.1M	Buy	727,000 +577,000	+385%	+$11.6M	0.53%	43
2025 Q4	$3.51M	Sell	150,000 -529,000	-78%	-$11.5M	0.13%	73
2025 Q3	$13.5M	Sell	679,000 -1,506,000	-69%	-$27M	0.68%	37
2025 Q2	$29.9M	Buy	+2,185,000	New	+$21M	1.98%	15
2024 Q2	–	Sell	-10,000	Closed	-$150K	–	112
2024 Q1	$150K	Buy	+10,000	New	+$163K	0.01%	89
2023 Q4	–	Sell	-372,000	Closed	-$5.21M	–	102
2023 Q3	$5.21M	Buy	+372,000	New	+$5.97M	0.48%	53

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Soleus Capital Management's URGN Position: Q2 2026 in Review

Soleus Capital Management increased its UroGen Pharma (URGN) stake by 14% in Q2 2026, buying an estimated $2.79M and bringing the position to 829,810 shares worth $30.5M. The position accounts for 1.05% of the portfolio, ranked #29.

Soleus Capital Management first reported a position in URGN in Q3 2023 and has held it in 7 quarters since. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Soleus Capital Management held 829,810 shares of UroGen Pharma worth $30.5M as of Q2 2026.
Soleus Capital Management bought 102,810 UroGen Pharma shares in Q2 2026, an estimated $2.79M.
UroGen Pharma made up 1.05% of Soleus Capital Management's portfolio in Q2 2026, its #29 holding.
Soleus Capital Management first reported a position in UroGen Pharma in Q3 2023 and has held it in 7 quarters since.
189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.